Email updates

Keep up to date with the latest news and content from Journal of Hematology & Oncology and BioMed Central.

Open Access Highly Accessed Review

Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers

Xinyuan Li1, Pu Fang1, Jietang Mai1, Eric T Choi2, Hong Wang1 and Xiao-feng Yang1*

Author Affiliations

1 Cardiovascular Research Center, Department of Pharmacology and Thrombosis Research Center, Temple University School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA

2 Cardiovascular Research Center and Department of Surgery, Temple University School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA

For all author emails, please log on.

Journal of Hematology & Oncology 2013, 6:19  doi:10.1186/1756-8722-6-19

Published: 25 February 2013

Abstract

There are multiple sources of reactive oxygen species (ROS) in the cell. As a major site of ROS production, mitochondria have drawn considerable interest because it was recently discovered that mitochondrial ROS (mtROS) directly stimulate the production of proinflammatory cytokines and pathological conditions as diverse as malignancies, autoimmune diseases, and cardiovascular diseases all share common phenotype of increased mtROS production above basal levels. Several excellent reviews on this topic have been published, but ever-changing new discoveries mandated a more up-to-date and comprehensive review on this topic. Therefore, we update recent understanding of how mitochondria generate and regulate the production of mtROS and the function of mtROS both in physiological and pathological conditions. In addition, we describe newly developed methods to probe or scavenge mtROS and compare these methods in detail. Thorough understanding of this topic and the application of mtROS-targeting drugs in the research is significant towards development of better therapies to combat inflammatory diseases and inflammatory malignancies.

Keywords:
Mitochondria; ROS; Inflammatory diseases